Vicore patent issued and positive trial results for IPF patients announced 23-May-2023 By Liza Laws Vicore Pharma’s drug candidate, C21 formulation, currently in a phase 2a trial aimed at people with idiopathic pulmonary fibrosis (IPF), has been patented.